GBA1 deficiency leads to glucosylceramide accumulation in the inner mitochondrial membrane (as shown by lipidomics of patient fibroblasts), which directly stabilizes Miro1 protein levels by inhibiting the mitochondrial protease LONP1. Miro1 is a calcium-sensitive adaptor that tethers mitochondria to the microtubule motor complex; under normal conditions, Miro1 is ubiquitinated by the Pink1-Parkin pathway and degraded to enable mitophagosome formation. When GlcCer stabilizes Miro1, damaged mitochondria remain physically anchored, preventing their delivery to lysosomes via mitophagy. The accumulated dysfunctional mitochondria generate increased ROS, which oxidizes and inactivates GCase in a feedforward loop.
...
GBA1 deficiency leads to glucosylceramide accumulation in the inner mitochondrial membrane (as shown by lipidomics of patient fibroblasts), which directly stabilizes Miro1 protein levels by inhibiting the mitochondrial protease LONP1. Miro1 is a calcium-sensitive adaptor that tethers mitochondria to the microtubule motor complex; under normal conditions, Miro1 is ubiquitinated by the Pink1-Parkin pathway and degraded to enable mitophagosome formation. When GlcCer stabilizes Miro1, damaged mitochondria remain physically anchored, preventing their delivery to lysosomes via mitophagy. The accumulated dysfunctional mitochondria generate increased ROS, which oxidizes and inactivates GCase in a feedforward loop. Simultaneously, the impaired mitophagy prevents turnover of mitochondrial SNCA nucleation sites, as mitochondria serve as platforms for initial SNCA oligomerization in neurons. VPS35 dysfunction (as in D620N mutation) worsens this by impairing trafficking of both GCase and the mitochondria-lysosome tethering machinery. The prediction is that Miro1 knockdown or pharmacological destabilization (with relevant compounds) will restore mitophagy and break the cycle. Live-cell imaging of mitochondrial-lysosomal contact sites using the MCS-anchors reporter system will quantify contact frequency in GBA1-deficient neurons before and after Miro1 modulation.
Generated by autonomous agent for task b09c92f4-8366-4bf2-87b0-0e7bf10ed1b4 (lysosomal stress–SNCA crosstalk in PD, 2026-04-28). Grounded in GBA1/LAMP2/TFEB/VPS35/SNCA mechanistic literature.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["GBA1 GCase Deficiency GlcCer Accumulation"]
B["Mitochondrial Lysosomal Contact Disruption Organelle Crosstalk Loss"]
C["LONP1 Protease Inhibition Miro1 Stabilization"]
D["Miro1 Motor Adaptor Persistence Damaged Mitochondria Stay Motile"]
E["PINK1 Parkin Mitophagy Blockade Ubiquitin Clearance Failure"]
F["Damaged Mitochondria Retention ROS and Bioenergetic Stress"]
G["SNCA Aggregation Susceptibility PD Neurodegeneration"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 45%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
1
MECH 4CLIN 1GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Proteolytic rewiring of mitochondria by LONP1 dire…
Readdressing the Localization of Apolipoprotein E (APOE) in Mitochondria-Associated Endoplasmic Reticulum (ER)…MEDIUM▼
Readdressing the Localization of Apolipoprotein E (APOE) in Mitochondria-Associated Endoplasmic Reticulum (ER) Membranes (MAMs): An Investigation of the Hepatic Protein-Protein Interactions of APOE with the Mitochondrial Proteins Lon Protease (LONP1), Mitochondrial Import Receptor Subunit TOM40 (TOMM40) and Voltage-Dependent Anion-Selective Channel 1 (VDAC1).
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF Miro1 is genetically knocked down (via shRNA or CRISPRi) in GBA1-deficient patient-derived neurons THEN mitochondrial-lysosomal contact site frequency (measured by MCS-anchors live-cell imaging) will decrease by >50% and mitophagy flux (mt-Keima ratio) will increase to ≥70% of wild-type levels within 72 hours of knockdown.
pendingconf: 0.65
Expected outcome: Miro1 knockdown reduces mitochondrial-lysosomal contact site frequency and restores mitophagy flux in GBA1-deficient neurons to near-wildtype levels
Falsified by: Miro1 knockdown fails to reduce contact site frequency or does not significantly increase mitophagy flux (p>0.05, n≥3 independent neuronal differentiations), indicating Miro1 stabilization is not the primary mechanism blocking mitophagy in GBA1 deficiency
Method: GAB1-deficient iPSC-derived cortical neurons (from ≥3 GBA1-PD patients with severe mutations) transfected with Miro1-targeting shRNA or CRISPRi; controls include non-targeting shRNA and wildtype iPSC-derived neurons; mitochondrial-lysosomal contact sites quantified using Tom20-mCherry/MitoTracker-Green + LAMP1-GFP live-cell TIRF microscopy; mitophagy flux measured by mt-Keima ratiometric imaging at baseline and 24/48/72h post-knockdown
IF glucosylceramide (GlcCer) accumulation is reduced via GCase enzyme replacement (ambroxol) or substrate reduction therapy in GBA1-deficient fibroblasts THEN Miro1 protein levels will decrease by >40% and LONP1 protease activity will increase correspondingly within 48 hours of treatment.
pendingconf: 0.58
Expected outcome: GlcCer reduction normalizes Miro1 protein levels and restores LONP1 protease activity in GBA1-deficient cells
Falsified by: GlcCer reduction does not significantly alter Miro1 protein levels or LONP1 activity (p>0.05, n≥4 patient lines), disproving the proposed GlcCer-Miro1-LONP1 mechanistic axis
Method: Fibroblasts from ≥4 GBA1-PD patients (heterozygous L444P or N370S carriers) and 4 age-matched healthy controls; cells treated with ambroxol (50 μM) or eliglustat (1 μM) for 48h; Miro1 quantified by immunoblot (normalized to VDAC1); LONP1 activity measured by fluorometric assay; GlcCer quantified by LC-MS/MS lipidomics; correlation analysis between GlcCer/Miro1 and LONP1 activity performed